pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
← back to CHIESI
News mentioning CHIESI
8
stories
3d
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Aug 14, 26
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
Aug 5, 26
A COPD drug from China draws $115M in venture funding
biopharma dive
Jul 27, 26
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
biospace
Jul 27, 26
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
Apr 29, 26
Chiesi to buy KalVista in $1.9B deal for rare disease drug
biopharma dive
Apr 29, 26
STAT+: A patent win for Pfizer and BridgeBio
stat
Apr 29, 26
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
endpoints
CHIESI · news · pharmadog
